TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01405235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/Paclitaxel
Description: Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
Study: NCT03773861

Intervention type: OTHER
Group type: OTHER
Intervention: errors made in one BLS session
Description: BLS instructors have to oversee a standardized BLS training session, where standardized errors are made by trained volunteers.
Study: NCT03360422

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
Study: NCT02449473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Subcutaneous Injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous Injection
Study: NCT02491996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: desire satisfaction-targeted intervention for disordered gamblers
Description: This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
Study: NCT04227041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib in combination with capecitabine
Description: Pyrotinib in combination with capecitabine
Study: NCT01919541

Intervention type: OTHER
Group type: OTHER
Intervention: Prehabilitation
Description: All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.

Intervention type: DEVICE
Group type: OTHER
Intervention: hyperinsulinemic euglycemic isoaminoacid clamp
Description: A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.

Intervention type: DEVICE
Group type: OTHER
Intervention: hyperinsulinemic euglycemic hyperaminoacid clamp

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: whey protein supplementation

Intervention type: OTHER
Group type: OTHER
Intervention: Prehabilitation
Description: All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
Study: NCT00706719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Androxal
Description: 25 mg Androxal capsules, 1 capsule daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Androxal
Description: 25 mg Androxal capsules, 1 capsule daily for 6 months
Study: NCT03360422

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Focus Group
Description: After informed consent, participants will complete the web-based intervention component in development. Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usability study
Description: After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
Study: NCT01662180

Intervention type: DRUG
Intervention: Follicle Stimulating Hormone
Description: All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
Study: NCT02954848

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-438 placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438 10 mg
Description: TAK-438 tablets
Study: NCT02206386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MHTraining-Net
Description: See Arm Description for more details.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Support
Description: Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
Study: NCT01835899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: medium dose 1 powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: medium dose 2 powder for oral solution
Study: NCT04785209

Intervention type: OTHER
Intervention: Mean platelet volume, lymphocyte number, STEMI clinical risk scores
Description: Lab parameters

Intervention type: OTHER
Intervention: Mean platelet volume, lymphocyte number, STEMI clinical risk scores
Description: Lab parameters
Study: NCT03278561

Intervention type: PROCEDURE
Intervention: Sputum induction
Description: Sputum induction according to the ERS protocol

Intervention type: PROCEDURE
Intervention: Sputum induction
Description: Sputum induction according to the ERS protocol

Intervention type: PROCEDURE
Intervention: Sputum induction
Description: Sputum induction according to the ERS protocol

Intervention type: PROCEDURE
Intervention: Blood sample
Description: A blood sample of 100ml will be taken.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: A blood sample of 100ml will be taken.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: A blood sample of 100ml will be taken.
Study: NCT05059275

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified ostium obstruction surgery
Description: An ostium at the end of the site where the nerve root enters the dural sac, from which CSF could flow continuously along the subarachnoid space, was identified An appropriate amount of autologous soft adipose tissue was removed under the skin of the incision or deep in the upper part of the buttock (Iliac spine incision, for less subcutaneous fat patients). It was then trimmed to resemble a gourd or dumbbell, with a relatively small middle section and two relatively large end sections. Trimmed graft was inserted into the neck of the sac and subarachnoid space below the dural sac so that it plugs the ostium inside and outside After filling the graft, Prolene 6-0 was used to continuously suture and close the ostium and dural sac starting from the lower part of the nerve root sheath and the ostium.The residual cyst cavity filled with autologous fat and gelatin sponge
Study: NCT00284128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE7688
Description: oral administration (capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE7688
Description: oral administration (capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE7688
Description: oral administration (capsules)
Study: NCT01835899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI1015550
Description: low dose 2 powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: low dose 1 powder for oral solution
Study: NCT03651713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GLU+EX
Description: Subjects will complete 45 minutes of recumbent cycling at 60-65% of age-predicted maximal heart rate five times over seven days while ingesting a 75g glucose beverage three times daily.
Study: NCT00284128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE7688
Description: oral administration (capsules)
Study: NCT03651713

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GLU
Description: Subjects will consume a 75g glucose beverage three times daily over a seven-day period.
Study: NCT02012543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agar jelly
Study: NCT00706719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim 1%
Description: Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
Study: NCT00284128

Intervention type: DRUG
Group type: OTHER
Intervention: Losartan-potassium
Description: oral administration (capsules)
Study: NCT01224314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Changing potassium concentration in dialysis fluids
Description: The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Changing potassium concentration in dialysis fluids
Description: The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l
Study: NCT02488161

Intervention type: OTHER
Intervention: No intervention
Study: NCT02346552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AutoLap
Study: NCT04549857

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: aromatherapy
Description: The intervention measures were taught by the researchers to perform self-massage on both wrists and finger joints in the experimental group and the comfort group, using 5ml each time (2.5ml each for one hand), 10 minutes each time (5 minutes for each hand), three times a week, It lasts for three weeks. The massage steps refer to dōTERRA's Aroma Touch Hand Technique. Before self-massage is performed, a professional must first ensure that the execution process is correct and the professional will use the phone to follow up weekly.~1. The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.~2. The placebo group only used base oil (sweet almond oil).~3. The control group did not provide any interventional measures and only received conventional treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: The intervention measures were taught by the researchers to perform self-massage on both wrists and finger joints in the experimental group and the comfort group, using 5ml each time (2.5ml each for one hand), 10 minutes each time (5 minutes for each hand), three times a week, It lasts for three weeks. The massage steps refer to dōTERRA's Aroma Touch Hand Technique. Before self-massage is performed, a professional must first ensure that the execution process is correct and the professional will use the phone to follow up weekly.~1. The experimental group used the base oil (sweet almond oil) to add Atlantic cedar, sweet marjoram and sweet orange essential oils. The essential oils were blended into 5% massage oil at a ratio of 3:1:1.~2. The placebo group only used base oil (sweet almond oil).~3. The control group did not provide any interventional measures and only received conventional treatment.
Study: NCT02010710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFANT software
Description: The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.
Study: NCT00785928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
Study: NCT03551067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine mixed with juice was given to the child orally preoperatively.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam/Ketamine
Description: Midazolam/Ketamine was mixed with juice and given to the child orally preoperatively
Study: NCT03765931

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline
Description: The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
Study: NCT04458831

Intervention type: DRUG
Intervention: isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT03765931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin
Description: The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged \> 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature \> 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature \< 37.5°C.
Study: NCT04458831

Intervention type: DRUG
Intervention: Pomalidomide
Description: Pharmaceutical form: oral

Intervention type: DRUG
Intervention: Dexamethasone
Description: Pharmaceutical form: oral

Intervention type: DRUG
Intervention: Carfilzomib
Description: Pharmaceutical form: solution for infusion
Study: NCT03931551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]
Description: Participants will receive olaparib (300 mg tablets, orally twice daily during 21-day cycles) in combination with herceptin (intravenous dose of 4 mg/kg body weight with subsequent weekly doses of 2 mg/kg or subcutaneous dose of 600 mg every 3 weeks) until progression or unacceptable toxicity.
Study: NCT02551783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urethroplasty with buccal mucosa graft
Description: A surgery to correct urethral stricture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventral Buccal
Description: Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
Study: NCT03528733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Energy Digital Radiography Detector System
Description: A Multi-energy digital flat panel detector for Single Exposure Dual-Energy Subtraction radiography is developed to capture x-ray images with improved tissue differentiation. Tissue-selective images can be produced at various tissue levels such as bone and soft tissue to visualize obscured anomalies that are not apparent to General Radiography.
Study: NCT04617860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-120102
Description: WVE-120102 is a stereopure antisense oligonucleotide. It is administered monthly via intrathecal injection.
Study: NCT04189614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cofetuzumab Pelidotin
Description: Intravenous (IV) infusion
Study: NCT04687930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: genicular nerve block
Description: nerve block of the genicular nerve at 3 points around the inflamed knee using ultrasound.

Intervention type: DRUG
Group type: OTHER
Intervention: intra-articular steroid injection
Description: Triamcinilone injection into the knee joint under ultrasound guidance.
Study: NCT01762540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisolone 37.5 mg x1 for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Supplement
Description: Placebo
Study: NCT02670291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagPro Cool-B65A/P, Magventure
Description: combined active and sham coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: MagPro Cool-B65A/P, Magventure
Description: combined active and sham coil
Study: NCT00478257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bright white light
Description: Intervention: Bright white light administered for 30 minutes each morning

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comparator red light treatment
Description: dim red light administered for 30 minutes every morning
Study: NCT03439748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Treatment
Description: Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Negative Affect Treatment
Description: Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
Study: NCT03091062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vest® Airway Clearance System
Description: High frequency chest wall oscillation (HFCWO) therapy is commonly prescribed to provide routine airway clearance in patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow that is thought to mobilize secretions by the sheer force created.
Study: NCT00540631

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)
Description: Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~1. to be det. A 0.1 100 TU~2. 7 (+7) days later A 0.2 200 TU~3. 7 (+7) days later A 0.4 400 TU~4. 7 (+7) days later A 0.6 600 TU~5. 7 (+7) days later B 0.1 1000 TU~6. 7 (+7) days later B 0.2 2000 TU~7. 7 (+7) days later B 0.4 4000 TU~8. 7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued
Study: NCT04548960

Intervention type: OTHER
Group type: OTHER
Intervention: cancer patients
Description: Blood sample RNA_seq at time of diagnostic, best response and relapse ; Biopsy Exom_seq and RNA_seq at time of diagnostic and relapse Immulogical Profiling at time of diagnostic, best response and relapse
Study: NCT00711373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hand transplantation
Description: Surgical reconstruction of part or all of the hands and/or hands and forearm using tissue from a non-living donor
Study: NCT04440280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine (NAC) 10% solution
Description: N-acetyl cysteine is a sterile, unpreserved eye drop containing 10% (100 mg/mL) of acetylcysteine.
Study: NCT03318094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine
Description: Intrabrachial phentolamine will be given on the blocked day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intrabrachial saline will be given this day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside
Description: Intrabrachial sodium nitroprusside will be given this day to compare with phentolamine